One pill to beat worms? new drug emodepside takes on mebendazole

NCT ID NCT06736691

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a single dose of emodepside can cure soil-transmitted worm infections (like whipworm, hookworm, and roundworm) better than the standard 3-day course of mebendazole. About 315 adolescents and adults with confirmed infections will receive either emodepside or mebendazole, and researchers will check stool samples to see if the worms are gone. The goal is to find a simpler, more effective treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
emodepside
What this could lead to
If it works, this could offer a simpler, single-dose treatment for common worm infections, potentially improving cure rates and reducing the need for multiple doses.
What could go wrong
This is a single-center trial with 315 participants, so results may not apply broadly. Emodepside is new for this use, and side effects or lower-than-expected efficacy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASCARIS LUMBRICOIDES INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Public Health Laboratory - Ivo de Carneri (PHL-IdC)

    Chake Chake, Tanzania

More trials for these conditions

Other studies related to the condition(s) this trial covers.